drugset / Trial / NCT00939484

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

NCT00939484

Phase 2 Completed 31 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.

Timeline

Start
2009-06
Primary completion
2013-05
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vismodegib Small molecule Oral

Indications